Patients in the United States now have access to an oral GLP-1 treatment for obesity from Novo Nordisk, with a competing pill from Eli Lilly expected to gain approval later this year. The shift from injections to pills marks a new phase in the fast-growing market for medical weight loss, as drugmakers race to meet demand and regulators weigh new applications.
The change matters for patients who prefer pills over weekly injections and for insurers deciding coverage policies. It also raises fresh questions about safety, supply, and long-term use as these medicines move into wider use.
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
What Are GLP-1 Drugs and Why They Matter
GLP-1 drugs were first used for type 2 diabetes. They work by affecting appetite and blood sugar. In recent years, higher-dose versions for obesity have shown strong weight loss in clinical trials, helping move these medicines into mainstream care.
Public health needs are large. More than four in ten U.S. adults live with obesity, a condition tied to heart disease, stroke, and some cancers. Doctors and patients are seeking options that are effective, safer than older treatments, and easier to use.
Until now, most widely used GLP-1 options for weight management required injections. An approved pill opens a new option for those wary of needles, potentially improving adherence for some patients.
Competition and the Regulatory Outlook
Novo Nordisk’s oral obesity pill is already on the market, marking the first of its kind available to patients. Eli Lilly’s rival oral medicine is expected to clear U.S. regulators later this year, setting up direct competition between the two drugmakers that already dominate injectable GLP-1 therapies.
The timing matters. If approvals and launches arrive as projected, pharmacies and health plans will need to prepare for rapid uptake. The FDA’s review will also shape labeling, safety warnings, and use in specific patient groups.
Access, Pricing, and Coverage Questions
Access will depend on price, insurance coverage, and supply. Payers often require prior authorization for anti-obesity medications, and employers vary in what plans cover. A pill could lower barriers for some patients, but cost-sharing may still be high.
Supply has been a concern for injectable GLP-1 drugs at times, with demand outpacing production. Manufacturers will face pressure to ensure stable availability of pills if uptake accelerates.
Doctors point to the need for ongoing follow-up. Weight often returns when treatment stops, so long-term plans and coverage policies will shape outcomes.
Safety and Clinical Guidance
GLP-1 medicines commonly cause nausea, vomiting, and diarrhea, especially during dose escalation. Clinicians often recommend gradual titration to manage these effects. There are also rare but serious risks that require monitoring.
Experts say patients should consult clinicians about medical history, including pancreatitis, gallbladder disease, and other conditions that could affect treatment choice. Lifestyle support remains a core part of care alongside medication.
What to Watch Next
- FDA’s decision and labeling for Eli Lilly’s oral drug.
- Insurance coverage policies and employer plan adoption.
- Real-world adherence and side-effect profiles for pills versus injections.
- Manufacturing capacity and pharmacy availability.
The arrival of an approved pill and the prospect of a second competitor signal a meaningful shift for patients seeking medical weight loss. With demand high, the contest between Novo Nordisk and Eli Lilly will likely focus on efficacy, tolerability, ease of use, and coverage.
As regulators decide on the next approval and payers update policies, patients and clinicians will look for clear guidance on who benefits most, how to manage side effects, and how to maintain weight loss over time. The next year will show whether oral options can broaden access and deliver consistent results in everyday care.
